abstract |
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including pure red cell aplasia (PRCA). Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided. |